Free Trial

Gyre Therapeutics (GYRE) Institutional Ownership

Gyre Therapeutics logo
$13.12 -0.72 (-5.20%)
(As of 11/15/2024 ET)

Institutional Ownership Changes (13F Filings) for Gyre Therapeutics (NASDAQ:GYRE)

Current
Institutional Ownership
Percentage
23.99%
Number of
Institutional Buyers
(last 12 months)
10
Total
Institutional Inflows
(last 12 months)
$2.98M
Number of
Institutional Sellers
(last 12 months)
2
Total
Institutional Outflows
(last 12 months)
$229.27K
Get GYRE Insider Trade Alerts

Want to know when executives and insiders are buying or selling Gyre Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

Skip Chart & View Institutional Buying and Selling Data

GYRE Institutional Buying and Selling by Quarter

Gyre Therapeutics Major Shareholders & Ownership History

Reporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2024 Geode Capital Management LLC303,647$3.81M0.0%+16.9%0.325%
11/15/2024Barclays PLC9,288$116K0.0%+281.8%0.010%
11/15/2024 State Street Corp104,490$1.31M0.0%+8.8%0.112%
11/13/2024 FMR LLC3,742$47K0.0%N/A0.004%
11/13/2024 Advantage Alpha Capital Partners LP26,634$334K0.1%N/A0.029%
11/12/2024 Charles Schwab Investment Management Inc.113,648$1.43M0.0%+392.2%0.122%
8/14/2024 Marshall Wace LLP10,720$128K0.0%-58.0%0.013%
8/9/2024 Renaissance Technologies LLC13,900$166K0.0%N/A0.016%
8/9/2024 WINTON GROUP Ltd18,467$220K0.0%N/A0.022%
8/1/2024 Rhumbline Advisers10,291$123K0.0%N/A0.012%
7/26/2024 Bank of New York Mellon Corp18,266$218K0.0%N/A0.021%
5/10/2024 Vanguard Group Inc.195,098$3.41M0.0%-1.5%0.228%
(Data available from 1/1/2016 forward)

GYRE Institutional Ownership - Frequently Asked Questions

Who are the largest shareholders of GYRE shares?

During the previous two years, 12 institutional investors and hedge funds held shares of Gyre Therapeutics. The most heavily invested institutionals were Geode Capital Management LLC ($3.81M), Vanguard Group Inc. ($3.41M), Charles Schwab Investment Management Inc. ($1.43M), State Street Corp ($1.31M), Advantage Alpha Capital Partners LP ($334K), WINTON GROUP Ltd ($220K), and Bank of New York Mellon Corp ($218K).Learn more on GYRE's institutional investors.

What percentage of Gyre Therapeutics stock is owned by institutional investors?

23.99% of Gyre Therapeutics stock is owned by institutional investors. Learn more on GYRE's institutional investor holdings.

Which institutional investors have been buying Gyre Therapeutics stock?

Of the 10 institutional investors that purchased Gyre Therapeutics stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Charles Schwab Investment Management Inc. ($90.56K), Geode Capital Management LLC ($43.84K), Advantage Alpha Capital Partners LP ($26.63K), WINTON GROUP Ltd ($18.47K), Bank of New York Mellon Corp ($18.27K), Renaissance Technologies LLC ($13.90K), and Rhumbline Advisers ($10.29K).

How much institutional buying is happening at Gyre Therapeutics?

Institutional investors have bought a total of 240,964 shares in the last 24 months. This purchase volume represents approximately $2.98M in transactions.

Which Gyre Therapeutics major shareholders have been selling company stock?

The following institutional investors have sold Gyre Therapeutics stock in the last 24 months: Marshall Wace LLP ($14.82K), and Vanguard Group Inc. ($3.00K).

How much institutional selling is happening at Gyre Therapeutics?

Institutional investors have sold a total of 17,823 shares in the last 24 months. This volume of shares sold represents approximately $229.27K in transactions.



This page (NASDAQ:GYRE) was last updated on 11/17/2024 by MarketBeat.com Staff
From Our Partners